相似文献
1
Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.
Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1(Suppl 1):S41-7. doi: 10.1007/s00259-011-1769-1. Epub 2011 Apr 12.
2
Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
J Nucl Med. 2004 Aug;45(8):1366-72.
3
Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.
Q J Nucl Med Mol Imaging. 2013 Mar;57(1):79-91.
4
Acquisition settings for PET of 124I administered simultaneously with therapeutic amounts of 131I.
J Nucl Med. 2006 Aug;47(8):1375-81.
5
Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
J Nucl Med. 2008 Jun;49(6):1017-23. doi: 10.2967/jnumed.107.047159. Epub 2008 May 15.
6
124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison.
J Nucl Med. 2009 Nov;50(11):1844-7. doi: 10.2967/jnumed.109.066738. Epub 2009 Oct 16.
7
Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
J Nucl Med. 2006 Dec;47(12):1985-94.
8
9
Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):760-7. doi: 10.1007/s00259-002-0775-8. Epub 2002 Mar 27.
10
Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
J Nucl Med. 2016 Jul;57(7):1027-32. doi: 10.2967/jnumed.115.168799. Epub 2016 Feb 25.
引用本文的文献
1
Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories.
J Nucl Med. 2025 Apr 1;66(4):509-515. doi: 10.2967/jnumed.124.267927.
2
Biodistribution and radiation dosimetry of I-mIBG in adult patients with neural crest tumours and extrapolation to paediatric models.
EJNMMI Phys. 2024 Jan 3;11(1):3. doi: 10.1186/s40658-023-00604-0.
3
Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.
J Nucl Med. 2021 Dec;62(Suppl 3):12S-22S. doi: 10.2967/jnumed.121.262750.
4
Diagnostic Performance of I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma.
J Nucl Med. 2022 Jun;63(6):869-874. doi: 10.2967/jnumed.121.262797. Epub 2021 Sep 23.
5
Optimizing reconstruction parameters for quantitative I-PET in the presence of therapeutic doses of I.
EJNMMI Phys. 2021 Jul 12;8(1):50. doi: 10.1186/s40658-021-00398-z.
6
Recent advances in voxel-based targeted radionuclide therapy dosimetry.
Quant Imaging Med Surg. 2021 Feb;11(2):483-489. doi: 10.21037/qims-20-1006.
7
Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning.
Clinics (Sao Paulo). 2019;74:e835. doi: 10.6061/clinics/2019/e835. Epub 2019 Jul 29.
8
Thyroid Cancer Radiotheragnostics: the case for activity adjusted I therapy.
Clin Transl Imaging. 2018 Oct;6(5):335-346. doi: 10.1007/s40336-018-0291-x. Epub 2018 Aug 4.
9
Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.
Cancer Biother Radiopharm. 2019 Feb;34(1):13-23. doi: 10.1089/cbr.2018.2568. Epub 2018 Oct 23.
10
Combined model-based and patient-specific dosimetry for F-DCFPyL, a PSMA-targeted PET agent.
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):989-998. doi: 10.1007/s00259-018-3939-x. Epub 2018 Feb 19.
本文引用的文献
1
21 years of biologically effective dose.
Br J Radiol. 2010 Jul;83(991):554-68. doi: 10.1259/bjr/31372149.
2
131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.
J Nucl Med. 2010 Jul;51(7):1155-62. doi: 10.2967/jnumed.110.075176. Epub 2010 Jun 16.
3
Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy.
J Nucl Med. 2010 Apr;51(4):654-9. doi: 10.2967/jnumed.109.067298. Epub 2010 Mar 17.
4
Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.
Eur J Nucl Med Mol Imaging. 2010 May;37(5):884-95. doi: 10.1007/s00259-009-1351-2. Epub 2010 Jan 13.
5
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
Thyroid. 2009 Nov;19(11):1167-214. doi: 10.1089/thy.2009.0110.
6
124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison.
J Nucl Med. 2009 Nov;50(11):1844-7. doi: 10.2967/jnumed.109.066738. Epub 2009 Oct 16.
7
Calculation of the biological effective dose for piecewise defined dose-rate fits.
Med Phys. 2009 Mar;36(3):904-7. doi: 10.1118/1.3070587.
8
Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry.
Med Phys. 2008 Mar;35(3):1123-34. doi: 10.1118/1.2836421.
9
Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET.
Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):502-8. doi: 10.1007/s00259-007-0601-4. Epub 2007 Nov 20.
10
Biologically-equivalent dose and long-term survival time in radiation treatments.
Phys Med Biol. 2007 Oct 21;52(20):6355-62. doi: 10.1088/0031-9155/52/20/017. Epub 2007 Oct 2.
Zotero 插件